Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naive and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control

Next Previous
Trial Profile

A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naive and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin/linagliptin (Primary) ; Empagliflozin; Linagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 15 Jun 2018 Results of pooled datea from two 52-week Phase III studies assessing the safety and tolerability of empagliflozin/linagliptin compared with their individual components published in the Advances in Therapy
    • 22 Nov 2016 According to a Boehringer Ingelheim media release, the European Commission has granted marketing authorization to Glyxambi (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). The approval is based on results from this and other two phase III trials (see profile 700226645 and 700228368).
    • 16 Sep 2016 According to a Boehringer Ingelheim Pharmaceuticals media release, the Committee for Medicinal Products for Human Use of the European Medicines Agency today recommended the approval of Glyxambi (empagliflozin/linagliptin) for use in adults with type 2 diabetes. Data from this and other two phase III trials supported this recommendations.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top